Other languages Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
0.7407 ^USD	-8.56%		+8.77%	+32.27%

May. 10	Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 25	Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	May. 10
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	Apr. 25
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	Apr. 22
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	Apr. 19
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 18
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	Jan. 05
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 30
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19
Tiziana Life Sciences Doses Four New Patients in Multiple-Sclerosis Program	Nov. 30
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis	Nov. 30
Tiziana Life Sciences Says FDA Allows At-Home Use of Multiple Sclerosis Treatment; Shares Rise	23-10-18
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment	23-10-18
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab	23-10-16
Tiziana Life Sciences Says Multiple Sclerosis Drug Reduced Key Biomarker Based on PET Scan Results	23-10-13
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)	23-10-13
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis	23-09-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Other languages

Filters